ModeX Therapeutics / OPKO
ModeX, an OPKO company, lists MDX3001 as in vivo CAR-T for cancer and autoimmunity. Its platform conjugates CD3×CD28 antibodies to LNPs carrying CAR mRNA. Human dosing and the program’s precise current stage were not established by the accessible pipeline text.
Corporate information
- Company entity
- ModeX Therapeutics / OPKO
- Headquarters / principal office
- Weston, Massachusetts, USAOffice location disclosed on the corporate website; a sole legal or global headquarters is not inferred. ↗
- Founded
- 2020 ↗
- Ownership / capital status
- Group subsidiary / business platformWholly owned OPKO Health subsidiary ↗
- Official corporate reference
- https://www.modextherapeutics.com/ ↗
- LinkedIn company page
- LinkedIn ↗ ↗
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
ModeX, an OPKO company, lists MDX3001 as in vivo CAR-T for cancer and autoimmunity. Its platform conjugates CD3×CD28 antibodies to LNPs carrying CAR mRNA. Human dosing and the program’s precise current stage were not established by the accessible pipeline text.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.
Original sources
- ModeX Therapeutics / OPKO — primary program / ownership disclosure
- Official company contact / corporate location disclosure
- OPKO acquisition of ModeX; founded October 2020